| Product Code: ETC13280533 | Publication Date: Apr 2025 | Updated Date: Jul 2025 | Product Type: Market Research Report | |
| Publisher: 6Wresearch | Author: Dhaval Chaurasia | No. of Pages: 190 | No. of Figures: 80 | No. of Tables: 40 |
According to 6Wresearch internal database and industry insights, the Global Lumasiran Market was valued at USD 0.25 Billion in 2024 and is expected to reach USD 0.46 Billion by 2031, growing at a compound annual growth rate of 6.20% during the forecast period (2025-2031).
The Global Lumasiran Market is experiencing significant growth driven by the rising prevalence of rare genetic diseases such as primary hyperoxaluria type 1 (PH1). Lumasiran, a RNA interference (RNAi) therapeutic, has shown promising results in treating PH1 by reducing the levels of oxalate production in the body. The increasing awareness about rare diseases, advancements in biotechnology, and a growing emphasis on personalized medicine are also contributing to the market expansion. Key players in the Global Lumasiran Market include Alnylam Pharmaceuticals, Inc., the company behind Lumasiran`s development and commercialization. As more clinical trials validate the efficacy and safety of Lumasiran, the market is expected to witness continued growth, offering new treatment options for patients with rare genetic disorders.
The Global Lumasiran Market is witnessing significant growth driven by the increasing prevalence of rare diseases such as primary hyperoxaluria type 1 (PH1) and the growing demand for innovative treatment options. Lumasiran, a novel RNA interference therapeutic, has shown promising results in reducing oxalate production and improving kidney function in patients with PH1. The market is expected to expand further with the rising awareness about rare diseases, advancements in genetic testing, and the increasing investment in research and development of RNA-based therapeutics. Opportunities lie in collaborations between pharmaceutical companies and research institutions to accelerate clinical trials, regulatory approvals, and market penetration. Additionally, the market could benefit from strategic partnerships for the commercialization and distribution of lumasiran in untapped regions, ultimately improving patient access to this life-changing treatment.
One of the key challenges faced in the Global Lumasiran Market is the limited awareness and understanding of this novel treatment among patients and healthcare providers. Lumasiran is a relatively new therapy for the treatment of primary hyperoxaluria type 1 (PH1), a rare genetic disorder, and its adoption may be hindered by the lack of knowledge about its benefits and potential impact on patient outcomes. Additionally, the high cost of lumasiran could pose a barrier to access for patients, particularly in regions with limited healthcare resources or where insurance coverage is inadequate. Overcoming these challenges would require targeted education efforts, improved affordability options, and increased advocacy for the recognition of lumasiran as a valuable treatment for PH1 patients.
The Global Lumasiran Market is primarily driven by the increasing prevalence of rare diseases such as primary hyperoxaluria type 1 (PH1) for which lumasiran is a promising treatment option. The rising awareness about rare genetic disorders, coupled with advancements in healthcare infrastructure and diagnostic capabilities, is fueling the demand for innovative therapies like lumasiran. Additionally, supportive regulatory initiatives and collaborations between pharmaceutical companies and research institutions are contributing to the growth of the lumasiran market. The potential for improved patient outcomes and the need for more effective treatments for rare diseases are driving the adoption of lumasiran globally. Overall, the market for lumasiran is expected to expand further as more patients seek access to this novel therapeutic option.
Government policies related to the Global Lumasiran Market primarily focus on regulatory approval processes, pricing and reimbursement mechanisms, and intellectual property rights protection. Regulatory bodies such as the FDA in the United States and the EMA in Europe play a crucial role in evaluating the safety and efficacy of lumasiran for the treatment of rare diseases like primary hyperoxaluria type 1. Pricing and reimbursement policies vary by country, with some governments implementing measures to ensure affordability and access to innovative therapies. Intellectual property rights protection is also a key consideration, as companies developing lumasiran seek to secure patents to incentivize investment in research and development. Overall, government policies impact market access, pricing strategies, and innovation within the Global Lumasiran Market.
The Global Lumasiran Market is poised for significant growth in the coming years, driven by the increasing prevalence of rare diseases such as primary hyperoxaluria type 1 (PH1) and the growing adoption of advanced RNA interference (RNAi) therapeutics. Lumasiran, a novel RNAi therapeutic developed by Alnylam Pharmaceuticals, has shown promising results in clinical trials for treating PH1, a rare genetic disorder that can lead to kidney failure. As more patients are diagnosed with PH1 and other rare diseases, the demand for effective treatments like lumasiran is expected to rise. Additionally, the expanding healthcare infrastructure in emerging markets and ongoing research and development efforts in the field of RNAi therapeutics will further propel the growth of the global lumasiran market in the future.
In the global Lumasiran market, Asia is expected to witness significant growth due to increasing awareness about rare diseases and improving healthcare infrastructure. North America is poised to dominate the market with the presence of key market players and advanced healthcare facilities. Europe is also a key market for Lumasiran, driven by rising investments in research and development activities. The Middle East and Africa region is projected to experience steady growth as healthcare systems continue to evolve. Latin America is likely to show promising growth opportunities as the adoption of novel therapies increases in the region. Overall, the global Lumasiran market is anticipated to showcase robust growth across all regions, with varying degrees of market penetration and adoption rates.
Global Lumasiran Market |
1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 Global Lumasiran Market Overview |
3.1 Global Regional Macro Economic Indicators |
3.2 Global Lumasiran Market Revenues & Volume, 2021 & 2031F |
3.3 Global Lumasiran Market - Industry Life Cycle |
3.4 Global Lumasiran Market - Porter's Five Forces |
3.5 Global Lumasiran Market Revenues & Volume Share, By Regions, 2021 & 2031F |
3.6 Global Lumasiran Market Revenues & Volume Share, By Drug Class, 2021 & 2031F |
3.7 Global Lumasiran Market Revenues & Volume Share, By Application, 2021 & 2031F |
3.8 Global Lumasiran Market Revenues & Volume Share, By Dosage form, 2021 & 2031F |
3.9 Global Lumasiran Market Revenues & Volume Share, By Route of Administration, 2021 & 2031F |
3.10 Global Lumasiran Market Revenues & Volume Share, By End-Users, 2021 & 2031F |
3.11 Global Lumasiran Market Revenues & Volume Share, By Distribution Channel, 2021 & 2031F |
4 Global Lumasiran Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.3 Market Restraints |
5 Global Lumasiran Market Trends |
6 Global Lumasiran Market, 2021 - 2031 |
6.1 Global Lumasiran Market, Revenues & Volume, By Drug Class, 2021 - 2031 |
6.1.1 Overview & Analysis |
6.1.2 Global Lumasiran Market, Revenues & Volume, By Miscellaneous Metabolic Agents, 2021 - 2031 |
6.1.3 Global Lumasiran Market, Revenues & Volume, By others, 2021 - 2031 |
6.2 Global Lumasiran Market, Revenues & Volume, By Application, 2021 - 2031 |
6.2.1 Overview & Analysis |
6.2.2 Global Lumasiran Market, Revenues & Volume, By Primary Hyperoxaluria, 2021 - 2031 |
6.2.3 Global Lumasiran Market, Revenues & Volume, By Others, 2021 - 2031 |
6.3 Global Lumasiran Market, Revenues & Volume, By Dosage form, 2021 - 2031 |
6.3.1 Overview & Analysis |
6.3.2 Global Lumasiran Market, Revenues & Volume, By Injection, 2021 - 2031 |
6.3.3 Global Lumasiran Market, Revenues & Volume, By Solution, 2021 - 2031 |
6.4 Global Lumasiran Market, Revenues & Volume, By Route of Administration, 2021 - 2031 |
6.4.1 Overview & Analysis |
6.4.2 Global Lumasiran Market, Revenues & Volume, By Subcutaneous, 2021 - 2031 |
6.4.3 Global Lumasiran Market, Revenues & Volume, By Demographic, 2021 - 2031 |
6.4.4 Global Lumasiran Market, Revenues & Volume, By Adult, 2021 - 2031 |
6.4.5 Global Lumasiran Market, Revenues & Volume, By Pediatric, 2021 - 2031 |
6.5 Global Lumasiran Market, Revenues & Volume, By End-Users, 2021 - 2031 |
6.5.1 Overview & Analysis |
6.5.2 Global Lumasiran Market, Revenues & Volume, By Clinics, 2021 - 2031 |
6.5.3 Global Lumasiran Market, Revenues & Volume, By Hospitals, 2021 - 2031 |
6.5.4 Global Lumasiran Market, Revenues & Volume, By Diagnostic center, 2021 - 2031 |
6.6 Global Lumasiran Market, Revenues & Volume, By Distribution Channel, 2021 - 2031 |
6.6.1 Overview & Analysis |
6.6.2 Global Lumasiran Market, Revenues & Volume, By Hospital Pharmacy, 2021 - 2031 |
6.6.3 Global Lumasiran Market, Revenues & Volume, By Retail Pharmacy, 2021 - 2031 |
6.6.4 Global Lumasiran Market, Revenues & Volume, By Online Pharmacy, 2021 - 2031 |
7 North America Lumasiran Market, Overview & Analysis |
7.1 North America Lumasiran Market Revenues & Volume, 2021 - 2031 |
7.2 North America Lumasiran Market, Revenues & Volume, By Countries, 2021 - 2031 |
7.2.1 United States (US) Lumasiran Market, Revenues & Volume, 2021 - 2031 |
7.2.2 Canada Lumasiran Market, Revenues & Volume, 2021 - 2031 |
7.2.3 Rest of North America Lumasiran Market, Revenues & Volume, 2021 - 2031 |
7.3 North America Lumasiran Market, Revenues & Volume, By Drug Class, 2021 - 2031 |
7.4 North America Lumasiran Market, Revenues & Volume, By Application, 2021 - 2031 |
7.5 North America Lumasiran Market, Revenues & Volume, By Dosage form, 2021 - 2031 |
7.6 North America Lumasiran Market, Revenues & Volume, By Route of Administration, 2021 - 2031 |
7.7 North America Lumasiran Market, Revenues & Volume, By End-Users, 2021 - 2031 |
7.8 North America Lumasiran Market, Revenues & Volume, By Distribution Channel, 2021 - 2031 |
8 Latin America (LATAM) Lumasiran Market, Overview & Analysis |
8.1 Latin America (LATAM) Lumasiran Market Revenues & Volume, 2021 - 2031 |
8.2 Latin America (LATAM) Lumasiran Market, Revenues & Volume, By Countries, 2021 - 2031 |
8.2.1 Brazil Lumasiran Market, Revenues & Volume, 2021 - 2031 |
8.2.2 Mexico Lumasiran Market, Revenues & Volume, 2021 - 2031 |
8.2.3 Argentina Lumasiran Market, Revenues & Volume, 2021 - 2031 |
8.2.4 Rest of LATAM Lumasiran Market, Revenues & Volume, 2021 - 2031 |
8.3 Latin America (LATAM) Lumasiran Market, Revenues & Volume, By Drug Class, 2021 - 2031 |
8.4 Latin America (LATAM) Lumasiran Market, Revenues & Volume, By Application, 2021 - 2031 |
8.5 Latin America (LATAM) Lumasiran Market, Revenues & Volume, By Dosage form, 2021 - 2031 |
8.6 Latin America (LATAM) Lumasiran Market, Revenues & Volume, By Route of Administration, 2021 - 2031 |
8.7 Latin America (LATAM) Lumasiran Market, Revenues & Volume, By End-Users, 2021 - 2031 |
8.8 Latin America (LATAM) Lumasiran Market, Revenues & Volume, By Distribution Channel, 2021 - 2031 |
9 Asia Lumasiran Market, Overview & Analysis |
9.1 Asia Lumasiran Market Revenues & Volume, 2021 - 2031 |
9.2 Asia Lumasiran Market, Revenues & Volume, By Countries, 2021 - 2031 |
9.2.1 India Lumasiran Market, Revenues & Volume, 2021 - 2031 |
9.2.2 China Lumasiran Market, Revenues & Volume, 2021 - 2031 |
9.2.3 Japan Lumasiran Market, Revenues & Volume, 2021 - 2031 |
9.2.4 Rest of Asia Lumasiran Market, Revenues & Volume, 2021 - 2031 |
9.3 Asia Lumasiran Market, Revenues & Volume, By Drug Class, 2021 - 2031 |
9.4 Asia Lumasiran Market, Revenues & Volume, By Application, 2021 - 2031 |
9.5 Asia Lumasiran Market, Revenues & Volume, By Dosage form, 2021 - 2031 |
9.6 Asia Lumasiran Market, Revenues & Volume, By Route of Administration, 2021 - 2031 |
9.7 Asia Lumasiran Market, Revenues & Volume, By End-Users, 2021 - 2031 |
9.8 Asia Lumasiran Market, Revenues & Volume, By Distribution Channel, 2021 - 2031 |
10 Africa Lumasiran Market, Overview & Analysis |
10.1 Africa Lumasiran Market Revenues & Volume, 2021 - 2031 |
10.2 Africa Lumasiran Market, Revenues & Volume, By Countries, 2021 - 2031 |
10.2.1 South Africa Lumasiran Market, Revenues & Volume, 2021 - 2031 |
10.2.2 Egypt Lumasiran Market, Revenues & Volume, 2021 - 2031 |
10.2.3 Nigeria Lumasiran Market, Revenues & Volume, 2021 - 2031 |
10.2.4 Rest of Africa Lumasiran Market, Revenues & Volume, 2021 - 2031 |
10.3 Africa Lumasiran Market, Revenues & Volume, By Drug Class, 2021 - 2031 |
10.4 Africa Lumasiran Market, Revenues & Volume, By Application, 2021 - 2031 |
10.5 Africa Lumasiran Market, Revenues & Volume, By Dosage form, 2021 - 2031 |
10.6 Africa Lumasiran Market, Revenues & Volume, By Route of Administration, 2021 - 2031 |
10.7 Africa Lumasiran Market, Revenues & Volume, By End-Users, 2021 - 2031 |
10.8 Africa Lumasiran Market, Revenues & Volume, By Distribution Channel, 2021 - 2031 |
11 Europe Lumasiran Market, Overview & Analysis |
11.1 Europe Lumasiran Market Revenues & Volume, 2021 - 2031 |
11.2 Europe Lumasiran Market, Revenues & Volume, By Countries, 2021 - 2031 |
11.2.1 United Kingdom Lumasiran Market, Revenues & Volume, 2021 - 2031 |
11.2.2 Germany Lumasiran Market, Revenues & Volume, 2021 - 2031 |
11.2.3 France Lumasiran Market, Revenues & Volume, 2021 - 2031 |
11.2.4 Rest of Europe Lumasiran Market, Revenues & Volume, 2021 - 2031 |
11.3 Europe Lumasiran Market, Revenues & Volume, By Drug Class, 2021 - 2031 |
11.4 Europe Lumasiran Market, Revenues & Volume, By Application, 2021 - 2031 |
11.5 Europe Lumasiran Market, Revenues & Volume, By Dosage form, 2021 - 2031 |
11.6 Europe Lumasiran Market, Revenues & Volume, By Route of Administration, 2021 - 2031 |
11.7 Europe Lumasiran Market, Revenues & Volume, By End-Users, 2021 - 2031 |
11.8 Europe Lumasiran Market, Revenues & Volume, By Distribution Channel, 2021 - 2031 |
12 Middle East Lumasiran Market, Overview & Analysis |
12.1 Middle East Lumasiran Market Revenues & Volume, 2021 - 2031 |
12.2 Middle East Lumasiran Market, Revenues & Volume, By Countries, 2021 - 2031 |
12.2.1 Saudi Arabia Lumasiran Market, Revenues & Volume, 2021 - 2031 |
12.2.2 UAE Lumasiran Market, Revenues & Volume, 2021 - 2031 |
12.2.3 Turkey Lumasiran Market, Revenues & Volume, 2021 - 2031 |
12.3 Middle East Lumasiran Market, Revenues & Volume, By Drug Class, 2021 - 2031 |
12.4 Middle East Lumasiran Market, Revenues & Volume, By Application, 2021 - 2031 |
12.5 Middle East Lumasiran Market, Revenues & Volume, By Dosage form, 2021 - 2031 |
12.6 Middle East Lumasiran Market, Revenues & Volume, By Route of Administration, 2021 - 2031 |
12.7 Middle East Lumasiran Market, Revenues & Volume, By End-Users, 2021 - 2031 |
12.8 Middle East Lumasiran Market, Revenues & Volume, By Distribution Channel, 2021 - 2031 |
13 Global Lumasiran Market Key Performance Indicators |
14 Global Lumasiran Market - Export/Import By Countries Assessment |
15 Global Lumasiran Market - Opportunity Assessment |
15.1 Global Lumasiran Market Opportunity Assessment, By Countries, 2021 & 2031F |
15.2 Global Lumasiran Market Opportunity Assessment, By Drug Class, 2021 & 2031F |
15.3 Global Lumasiran Market Opportunity Assessment, By Application, 2021 & 2031F |
15.4 Global Lumasiran Market Opportunity Assessment, By Dosage form, 2021 & 2031F |
15.5 Global Lumasiran Market Opportunity Assessment, By Route of Administration, 2021 & 2031F |
15.6 Global Lumasiran Market Opportunity Assessment, By End-Users, 2021 & 2031F |
15.7 Global Lumasiran Market Opportunity Assessment, By Distribution Channel, 2021 & 2031F |
16 Global Lumasiran Market - Competitive Landscape |
16.1 Global Lumasiran Market Revenue Share, By Companies, 2024 |
16.2 Global Lumasiran Market Competitive Benchmarking, By Operating and Technical Parameters |
17 Top 10 Company Profiles |
18 Recommendations |
19 Disclaimer |
Export potential enables firms to identify high-growth global markets with greater confidence by combining advanced trade intelligence with a structured quantitative methodology. The framework analyzes emerging demand trends and country-level import patterns while integrating macroeconomic and trade datasets such as GDP and population forecasts, bilateral import–export flows, tariff structures, elasticity differentials between developed and developing economies, geographic distance, and import demand projections. Using weighted trade values from 2020–2024 as the base period to project country-to-country export potential for 2030, these inputs are operationalized through calculated drivers such as gravity model parameters, tariff impact factors, and projected GDP per-capita growth. Through an analysis of hidden potentials, demand hotspots, and market conditions that are most favorable to success, this method enables firms to focus on target countries, maximize returns, and global expansion with data, backed by accuracy.
By factoring in the projected importer demand gap that is currently unmet and could be potential opportunity, it identifies the potential for the Exporter (Country) among 190 countries, against the general trade analysis, which identifies the biggest importer or exporter.
To discover high-growth global markets and optimize your business strategy:
Click Here